| 0.478 -0.042 (-8.09%) | 10-16 16:00 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term | |
|||
| Targets | 6-month : | 0.86  |
1-year : | 1.05 |
| Resists | First : | 0.74 |
Second : | 0.9 |
| Pivot price | 0.63 |
|||
| Supports | First : | 0.47 |
Second : | 0.39 |
| MAs | MA(5) : | 0.54 |
MA(20) : | 0.68 |
| MA(100) : | 0.91 |
MA(250) : | 1.07 |
|
| MACD | MACD : | -0.1 |
Signal : | -0.1 |
| %K %D | K(14,3) : | 6.3 |
D(3) : | 13.8 |
| RSI | RSI(14): 22.5 |
|||
| 52-week | High : | 1.62 | Low : | 0.47 |
Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is BEARISH in short-term; and BEARISH in mid-long term.[ LUCD ] has closed above bottom band by 7.8%. Bollinger Bands are 91% wider than normal. The large width of the bands suggest high volatility as compared to its normal range. The bands have been in this wide range for 10 days. This is a sign that the current trend might continue.
| If tomorrow: | Open lower | Open higher |
| High: | 0.53 - 0.53 | 0.53 - 0.53 |
| Low: | 0.46 - 0.47 | 0.47 - 0.47 |
| Close: | 0.47 - 0.48 | 0.48 - 0.48 |
Lucid Diagnostics Inc. is a commercial-stage medical technology firm focused on diagnostic solutions. The company's primary objective is to serve patients afflicted with gastroesophageal reflux disease (GERD), commonly referred to as chronic heartburn or acid reflux, especially those at increased risk of developing precancerous esophageal conditions or the particularly aggressive esophageal adenocarcinoma. Their key product offerings include EsoGuard, an internally developed esophageal DNA test, and EsoCheck, a specialized device designed for collecting esophageal cells. Formed in 2018, Lucid Diagnostics Inc. has its headquarters in New York, New York, and operates as a subsidiary of PAVmed Inc.
Fri, 16 Oct 2026
Lucid Diagnostics Receives Nasdaq Notice for Sub-$1 Bid Price, Faces Compliance Deadline - Kalkine Media
Fri, 16 Oct 2026
Lucid Diagnostics Disclosed Failure to Satisfy a Continued Listing Rule or Standard - TradingView
Tue, 22 Sep 2026
A new billing code was approved for a tool that collects esophageal cells. Medicare payment remains pending. - Stock Titan
Tue, 18 Aug 2026
Lucid Diagnostics Could Be 'High In The Queue' For Medicare Coverage Decision, Analyst Says - Benzinga
Thu, 13 Aug 2026
Lucid Diagnostics Provides Business Update and Reports Second Quarter 2026 Financial Results - PR Newswire
Thu, 13 Aug 2026
Lucid Diagnostics Inc. (LUCD) Reports Q2 Loss, Lags Revenue Estimates - Yahoo Finance
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Underperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Outperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Medical - Devices
|
|
| Shares Out | 191 (M) |
| Shares Float | 141 (M) |
| Held by Insiders | 26.5 (%) |
| Held by Institutions | 32.7 (%) |
| Shares Short | 13,460 (K) |
| Shares Short P.Month | 11,890 (K) |
| EPS | -0.44 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 0.05 |
| Profit Margin | 0 % |
| Operating Margin | -868.5 % |
| Return on Assets (ttm) | -81.7 % |
| Return on Equity (ttm) | -556.3 % |
| Qtrly Rev. Growth | 26.7 % |
| Gross Profit (p.s.) | -0.01 |
| Sales Per Share | 0.02 |
| EBITDA (p.s.) | -0.27 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -47 (M) |
| Levered Free Cash Flow | -26 (M) |
| PE Ratio | -1.09 |
| PEG Ratio | 0 |
| Price to Book value | 7.96 |
| Price to Sales | 16.74 |
| Price to Cash Flow | -1.95 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|